// App-Quantinova.ai

: Significance of alterations in DNA damage repair (DDR) genes in advanced biliary cancers (ABCs) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 trial.

Researchers

Presenter

  • Angela Lamarca

Principal Investigators

  • Harpreet Singh Wasan

  • Paul J. Ross

  • Yuk Ting Ma

  • Arvind Arora

  • Stephen Falk

  • Roopinder Gillmore

  • Jonathan Wadsley

  • Kinnari Patel

  • Alan Anthoney

  • Anthony Maraveyas

  • Claire Hobbs

  • Lorna Wilkinson

  • Timothy Macdonald

  • Claire Hartley

  • David Ryder

  • John A. Bridgewater

  • Juan W. Valle

Medical Centers

  • Manchester Medical School, University of Manchester, Manchester, United Kingdom

  • Newcastle Genetics Laboratory, Newcastle, United Kingdom

  • University Hospital Birmingham NHS Trust

  • Medical Oncology, Leeds, Leeds, United Kingdom

  • The Christie Hospital, Manchester, United Kingdom

  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • University of Manchester Clinical Trials Unit, Manchester, United Kingdom

  • Bristol Haematology and Oncology Centre, Bristol, United Kingdom

  • Hammersmith Hospital, Imperial College, London, United Kingdom

  • Oxford Cancer and Haematology Centre, Oxford, United Kingdom

  • Royal Free, London

  • Manchester Centre for Genomic Medicine, Manchester, United Kingdom

  • Swindon, Swindon, United Kingdom

  • University of Nottingham, Nottingham, United Kingdom

  • Department of Hepatobiliary Oncology, New Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Weston Park Hospital, Sheffield, United Kingdom

  • Bart's Cancer Institute, London, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • University of Liverpool, Liverpool, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Oxaliplatin

  • Oxaliplatin, 5-fluorouracil and folic acid

  • Adrucil injection

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT01926236

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved